The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Ogluo glucagon | Strongbridge Dublin Limited | Diabetes Mellitus | 🇪🇺 EU 2021-02-11 | Order → |
| Retsevmo selpercatinib | Eli Lilly Nederland B.V. | Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Cancer | 🇪🇺 EU 2021-02-11 | Order → |
| Sunitinib Accord sunitinib Generic | Accord Healthcare S.L.U. | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell; Neuroendocrine Tumors | 🇪🇺 EU 2021-02-11 | Order → |
| Tukysa tucatinib | Pfizer Europe MA EEIG | Breast Neoplasms; Neoplasm Metastasis | 🇪🇺 EU 2021-02-11 | Order → |
| Yuflyma adalimumab Biosimilar | Celltrion Healthcare Hungary Kft. | Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Spondylitis, Ankylosing; Uveitis; Hidradenitis Suppurativa; Colitis, Ulcerative; Crohn Disease; Arthriti | 🇪🇺 EU 2021-02-11 | Order → |
| Inrebic fedratinib Orphan | Bristol Myers Squibb Pharma EEIG | Myeloproliferative Disorders; Primary Myelofibrosis | 🇪🇺 EU 2021-02-08 | Order → |
| Lumoxiti moxetumomab pasudotox | AstraZeneca AB | Leukemia, Hairy Cell | 🇪🇺 EU 2021-02-08 | Order → |
| Kirsty (previously Kixelle) insulin aspart BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Diabetes Mellitus | 🇪🇺 EU 2021-02-05 | Order → |
| Rukobia fostemsavir Additional monitoring | ViiV Healthcare B.V. | HIV Infections | 🇪🇺 EU 2021-02-04 | Order → |
| Vaxzevria (previously COVID-19 Vaccine AstraZeneca) COVID-19 Vaccine (ChAdOx1-S [recombinant]) Additional monitoring | AstraZeneca AB | COVID-19 virus infection | 🇪🇺 EU 2021-01-29 | Order → |
| Enhertu trastuzumab deruxtecan ConditionalAdditional monitoring | Daiichi Sankyo Europe GmbH | Breast Neoplasms | 🇪🇺 EU 2021-01-18 | Order → |
| Onbevzi bevacizumab BiosimilarAdditional monitoring | Samsung Bioepis NL B.V. | Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | 🇪🇺 EU 2021-01-11 | Order → |
| Elzonris tagraxofusp OrphanExceptional circumstancesAdditional monitoring | Stemline Therapeutics B.V. | Lymphoma | 🇪🇺 EU 2021-01-07 | Order → |
| Roclanda latanoprost / netarsudil | Santen Oy | Glaucoma, Open-Angle; Ocular Hypertension | 🇪🇺 EU 2021-01-07 | Order → |
| Xofluza baloxavir marboxil Additional monitoring | Roche Registration GmbH | Influenza, Human | 🇪🇺 EU 2021-01-07 | Order → |
| Spikevax (previously COVID-19 Vaccine Moderna) COVID-19 mRNA vaccine Additional monitoring | Moderna Biotech Spain, S.L. | COVID-19 virus infection | 🇪🇺 EU 2021-01-06 | Order → |
| Comirnaty COVID-19 mRNA vaccine Additional monitoring | BioNTech Manufacturing GmbH | COVID-19 virus infection | 🇪🇺 EU 2020-12-21 | Order → |
| Phesgo pertuzumab;trastuzumab | Roche Registration GmbH | Breast Neoplasms | 🇪🇺 EU 2020-12-21 | Order → |
| Fintepla fenfluramine OrphanAdditional monitoring | UCB Pharma S.A. | Epilepsies, Myoclonic | 🇪🇺 EU 2020-12-18 | Order → |
| Lenalidomide Mylan lenalidomide Generic | Mylan Pharmaceuticals Limited | Multiple Myeloma | 🇪🇺 EU 2020-12-18 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.